StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)

Close on Nov 17, 2026Market cap $264.95MP/E –Yield –

Prelude Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Prelude Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$67.40M. For fiscal 2025 it was -$104.57M. The highest annual figure on record is -$28.11M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$104.57M–
FY2024Dec 31, 2024-$139.71M–
FY2023Dec 31, 2023-$132.28M–
FY2022Dec 31, 2022-$123.54M–
FY2021Dec 31, 2021-$113.74M–
FY2020Dec 31, 2020-$58.76M–
FY2019Dec 31, 2019-$28.11M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.45M–
Q1 FY2026Mar 31, 2026-$14.18M–
Q4 FY2025Dec 31, 2025-$17.35M–
Q3 FY2025Sep 30, 2025-$20.42M–
Q2 FY2025Jun 30, 2025-$32.19M–
Q1 FY2025Mar 31, 2025-$34.61M–
Q4 FY2024Dec 31, 2024-$33.83M–
Q3 FY2024Sep 30, 2024-$34.38M–
Q2 FY2024Jun 30, 2024-$37.16M–
Q1 FY2024Mar 31, 2024-$34.34M–
Q4 FY2023Dec 31, 2023-$37.38M–
Q3 FY2023Sep 30, 2023-$33.39M–
Q2 FY2023Jun 30, 2023-$32.40M–
Q1 FY2023Mar 31, 2023-$29.12M–
Q4 FY2022Dec 31, 2022-$33.39M–
Q3 FY2022Sep 30, 2022-$30.41M–
Q2 FY2022Jun 30, 2022-$29.46M–
Q1 FY2022Mar 31, 2022-$30.29M–
Q4 FY2021Dec 31, 2021-$33.01M–
Q3 FY2021Sep 30, 2021-$30.84M–
Q2 FY2021Jun 30, 2021-$27.92M–
Q1 FY2021Mar 31, 2021-$21.97M–
Q4 FY2020Dec 31, 2020-$19.45M–
Q3 FY2020Sep 30, 2020-$18.14M–
Q2 FY2020Jun 30, 2020-$11.44M–
Q1 FY2020Mar 31, 2020-$9.74M–
Q4 FY2019Dec 31, 2019-$10.10M–
Q3 FY2019Sep 30, 2019-$6.88M–

More Prelude Therapeutics figures

See a number that looks wrong?